Principal component analysis of general patterns of HIV-1 replicative fitness in different drug environments

Epidemics

Volumn 2, Issue 2, 2010, Pages 85-91

  Martins, João Z R ^a   Chappey, Colombe ^b   Haddad, Mojgan ^c   Whitcomb, Jeannette M ^c   Stawiski, Eric ^c   Petropoulos, Christos J ^c   Bonhoeffer, Sebastian ^a  

^a ETH ZURICH   (Switzerland)

^b GENENTECH INC   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

Author keywords

Combination; PCA; RC; Resistance; Therapy

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIMULATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PRINCIPAL COMPONENT ANALYSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SWITZERLAND; VIRUS REPLICATION;

EID: 77953685816     PISSN: 17554365     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.epidem.2010.03.003     Document Type: Article

References (24)

1. Barbour J., Wrin T., Grant R., Martin J., Segal M., Petropoulos C., and Deeks S. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol. 76 21 (2002) 11104-11112
2. Beaumont M., Zhang W., and Balding D. Approximate Bayesian computation in population genetics. Genetics 162 4 (2002) 2025-2035
3. Bennett D., Camacho R., Otelea D., Kuritzkes D., Fleury H., Kiuchi M., Heneine W., Kantor R., Jordan M., Schapiro J., et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance. PLoS ONE 4 3 (2009) Update
4. Bonhoeffer S., Chappey C., Parkin N., Whitcomb J., and Petropoulos C. Evidence for positive epistasis in HIV-1. Science 306 5701 (2004) 1547-1550
5. Chessel D., Dufour A.B., and Thioulouse J. The ade4 package-I: one-table methods. R News 4 1 (2004) 5-10
6. Daar E., Kesler K., Wrin T., Petropoulo C., Bates M., Lail A., Hellmann N., Gomperts E., Donfield S., et al. HIV-1 pol replication capacity predicts disease progression. Aids 19 9 (2005) 871
7. R Development Core Team. R: a language and environment for statistical computing (2008), R Foundation for Statistical Computing, Vienna, Austria URL http://www.R-project.org
8. Dykes C., Wang J., Jin X., Planelles V., An D., Tallo A., Huang Y., Wu H., and Demeter L. Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture. J. Clin. Microbiol. 44 6 (2006) 1930
9. Egger M., Hirschel B., Francioli P., Sudre P., Wirz M., Flepp M., Rickenbach M., Malinverni R., Vernazza P., and Battegay M. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Br. Med. J. 315 7117 (1997) 1194-1199
10. Gabriel K. The biplot graphic display of matrices with application to principal component analysis. Biometrika 58 3 (1971) 453-467
11. Gnanadesikan R. Methods for statistical data analysis of multivariate observations (1977), Wiley, New York
12. Gower J., and Hand D. Biplots (1996), Chapman & Hall/CRC
13. Hammer S., Katzenstein D., Hughes M., Gundacker H., Schooley R., Haubrich R., Henry W., Lederman M., Phair J., Niu M., et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N. Engl. J. Med. 335 15 (1996) 1081-1090
14. Hammer S., Eron Jr. J., Reiss P., Schooley R., Thompson M., Walmsley S., Cahn P., Fischl M., Gatell J., Hirsch M., et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300 5 (2008) 555
15. Harrigan P., and Larder B. Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates. Antimicrob. Agents Chemother. 46 3 (2002) 909-912
16. Jolliffe I. Principal component analysis (1986), Springer-Verlag, New York
17. Miao H., Dykes C., Demeter L., Cavenaugh J., Park S., Perelson A., and Wu H. Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments. Bull. Math. Biol. 70 6 (2008) 1749-1771
18. Mocroft A., Vella S., Benfield T., Chiesi A., Miller V., Gargalianos P., d'Arminio M., Yust I., Bruun J., Phillips A., et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352 9142 (1998) 1725
19. Palella F., Delaney K., Moorman A., Loveless M., Fuhrer J., Satten G., Aschman D., and Holmberg S. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338 13 (1998) 853-860
20. Petropoulos C., Parkin N., Limoli K., Lie Y., Wrin T., Huang W., Tian H., Smith D., Winslow G., Capon D., et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44 4 (2000) 920
21. Sax P., Tierney C., Collier A., Fischl M., Godfrey C., Jahed N., et al. ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naive subjects with screening HIV RNA=100,000 c/mL. Program and abstracts of the 17th International AIDS Conference (2008) 3-8
22. Turner D., Brenner B., and Wainberg M. Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type. Clin. Vaccine Immunol. (2003) 979-981
23. White K., Margot N., Wrin T., Petropoulos C., Miller M., and Naeger L. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46 11 (2002) 3437
24. Gentleman, R., Biocore, Geneplotter: Graphics related functions for Bioconductor, r package version 1.18.0.